Company news

Emergent BioSolutions Inc. news in 2025

Emergent BioSolutions Inc.'s news releases, calls and decks from 2025, newest first.

View company

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

December 12, 2025

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

November 18, 2025

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

November 12, 2025

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

October 29, 2025

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

October 28, 2025

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

October 8, 2025

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

September 24, 2025

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

September 19, 2025

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

September 15, 2025

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

September 9, 2025

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

September 2, 2025

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

August 29, 2025

Emergent BioSolutions to Participate in Upcoming Investor Conferences

August 27, 2025

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

August 21, 2025

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

August 6, 2025

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

July 28, 2025

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

July 28, 2025

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

July 15, 2025

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

July 8, 2025

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

July 2, 2025

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

June 23, 2025

Emergent BioSolutions Announces Addition to Russell 3000® Index

June 20, 2025

Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

June 5, 2025

Emergent BioSolutions Reports First Quarter 2025 Financial Results

May 7, 2025

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

May 1, 2025

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

April 22, 2025

Emergent BioSolutions Announces Stock Repurchase Program

March 31, 2025

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

March 20, 2025

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

March 19, 2025

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

March 18, 2025

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

March 13, 2025

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

March 12, 2025

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

March 10, 2025

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

March 3, 2025

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

February 18, 2025

Calls in 2025

Decks in 2025